Suppr超能文献

妊娠相关的药代动力学改变及其临床意义。

Pregnancy- Associated Changes in Pharmacokinetics and their Clinical Implications.

机构信息

Maccabi Health Services, Institute of Research and innovation, 4 Koifman st 8th floor, 6812509, Tel Aviv, Israel.

Soroka Medical Center, Department of Obstetrics and Gynecology, Beer Sheva, Israel.

出版信息

Pharm Res. 2018 Feb 12;35(3):61. doi: 10.1007/s11095-018-2352-2.

Abstract

PURPOSE

To critically review pregnancy-induced pharmacokinetic changes and their clinical application.

METHODS

Structured review of Pubmed, MBASE and published books.

RESULTS

For many drugs, advanced pregnancy is associated with lower maternal serum concentrations. As most drug concentrations are not measured routinely, such changes are not evident to the clinician. Moreover, even for drug concentrations measured clinically, one cannot interpret lower total drug levels as evidence of lower fraction of free drug, which is the pharmacologically- active component, due to lower protein binding of many drugs in late pregnancy. Higher fractions of free drug will lead to higher rate of hepatic metabolism, especially for high extraction medications, leading to lower total drug concentrations.. Pregnancy- induced larger volume of distribution will lead to lower peak of drugs and hence may impact the achievement therapeutic levels. To further complicate matters, the adherence of many women decreases during pregnancy, mostly due to fears of adverse fetal effects. These dynamic and complex processes make changes in recommendations for dose schedule very challenging and in many cases not practical.

CONCLUSIONS

Indeed, there are presently no pregnancy- targeted dose schedules, similar to existing dose changes, for example, in renal failure. Similar to the recent increased attention given to pharmacokinetic changes in pregnancy, well designed studies should compare dose-effect relationships in women receiving medications in different stages of pregnancy, to women receiving the same drug before, and/or after pregnancy. Whenever possible, women with chronic conditions can serve as their own controls and decrease the uncertainty created by inter- patient variability. Measuring drug effects in parallel to drug concentrations, will allow pharmacokinetic- pharmacodynamic modelling, leading to evidence-based decisions regarding changes in dose schedules during gestation.

摘要

目的

批判性地回顾妊娠引起的药代动力学变化及其临床应用。

方法

对 Pubmed、MBASE 和已出版书籍进行结构化综述。

结果

对于许多药物,妊娠晚期母体血清浓度较低。由于大多数药物浓度未常规测量,因此临床医生无法察觉到这些变化。此外,即使对临床测量的药物浓度,也不能将总药物水平较低解释为游离药物(即具有药理活性的药物)比例较低的证据,因为许多药物在妊娠晚期的蛋白结合率较低。较高的游离药物比例将导致更高的肝代谢率,特别是对于高提取药物,从而导致总药物浓度降低。妊娠引起的更大分布容积将导致药物峰值降低,从而可能影响达到治疗水平。更复杂的是,许多女性在怀孕期间的依从性下降,主要是因为担心对胎儿产生不良影响。这些动态和复杂的过程使得改变剂量方案的建议变得非常具有挑战性,在许多情况下并不实际。

结论

事实上,目前没有针对妊娠的靶向剂量方案,类似于现有的剂量变化,例如在肾功能衰竭的情况下。与最近对妊娠期间药代动力学变化的关注度增加类似,应设计良好的研究比较在不同妊娠阶段接受药物治疗的女性与在妊娠前和/或妊娠后接受相同药物的女性之间的剂量-效应关系。只要有可能,患有慢性疾病的女性可以作为自己的对照,并减少个体间变异性带来的不确定性。同时测量药物浓度和药物效果,将允许进行药代动力学-药效学建模,从而为妊娠期间改变剂量方案提供基于证据的决策。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验